Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Aditya Mehta

Advanced Heart Failure and Transplant Cardiology Salt Lake City, UT Medical Doctor

NPI 1487215893 CMS profile 11303453

30 N Mario Capecchi Dr Rm 3N100, Salt Lake City, UT 84112

Open in the dashboard

General payments

$3,612

40 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aditya Mehta of Salt Lake City, UT is reported in the CMS Open Payments database as having received $3,612 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,116 35
2023 General $481 4
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aditya Mehta
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Aditya Mehta were reported at $3,116. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Aditya Mehta Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $0 $863 $224–$4,562 $163
2020 $0 $452 $122–$3,992 $114
2021 $15 $550 $159–$3,571 $132
2022 $0 $729 $221–$4,357 $149
2023 $481 $1,002 $309–$5,827 $160
2024 $0 $931 $273–$5,204 $164
2025 $3,116 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $3,175 31 payments
  2. Amgen Inc. $216 2 payments
  3. Teleflex LLC $60 1 payment
  4. Actelion Pharmaceuticals US, Inc. $53 1 payment
  5. Takeda Pharmaceuticals U.S.A., Inc. $34 1 payment
  6. E.R. Squibb & Sons, L.L.C. $31 2 payments
  7. Abiomed $24 1 payment
  8. CVRx, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,726 30 payments
  2. Travel and Lodging $1,637 9 payments
  3. Education $249 1 payment
Products named General payments · program years 2021–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $1,769 17 payments
  2. 2ND GEN CENTRIMAG PRIMARY CONSOLE $1,107 11 payments
  3. ENSITE $249 1 payment
  4. Repatha $216 2 payments
  5. UPTRAVI $53 1 payment
  6. CARDIOMEMS $50 2 payments
  7. LIVTENCITY $34 1 payment
  8. ELIQUIS $31 2 payments
  9. Barostim Neo System $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

73

Median for Internal Medicine: 777

Drug cost

$960

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 18 $360
Valsartan Generic 15 $344
Atorvastatin Calcium Generic 15 $184
Spironolactone Generic 14 $52
Amlodipine Besylate Generic 11 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record